Novartis’s big wager on RNAi approaches the finish line
The Covid-19 pandemic might yet delay US approval of Novartis's cholesterol-lowering project Leqvio − and then come the commercial questions.
FDA sends Reata back to the drawing board
The need for another pivotal trial of omaveloxolone in Friedreich's ataxia looks increasingly likely.
The pandemic response roars on
As Regeneron’s antibody cocktail becomes the latest Covid-19 treatment to win US authorisation, Merck shows that the search for new options is not over.
Drug rejections rise as Covid-19 bites
Alkermes manages to shrug off yesterday’s complete response letter, but US knockbacks in 2020 are creeping up.
A lull in FDA Covid-19 test authorisations
Just as demand for coronavirus tests is peaking, the US regulator has a quiet week.
